Policies That Could Lead To Korean Biopharma Growth And Competitiveness
Industry Sees Regulatory Science Improvements As Key
A major South Korean pharma industry association provides multiple policy proposals to the country's new government, which it sees as supporting the sector’s growth and international competitiveness through improved regulatory science and other updated approaches.
You may also be interested in...
Based on promising Phase II data, two companies in South Korea are moving ahead with late-stage development in the gout space, with JW Pharmaceutical getting approvals to begin a multinational Phase III trial for epaminurad, while LG Chem has recently submitted an application for a Phase III program with its contender tigulixostat.
VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.
Scrip takes a look at the current landscape in the South Korean digital therapeutics sector, where some remaining gaps in regulation and reimbursement are seen but multiple products are now progressing through pivotal local clinical trials.